CDKN2A and glioblastoma: Although methylated MGMT status is recognized as the most robust predictive marker for patients with GBM, other genetic markers associated with prognosis, including EGFR amplification, TERT promoter mutation, chromosome 10 loss, and CDKN2A/B homozygous deletion, have also been reported.5, 6, 7, 8, 9